All In Biotech

Drug Trial Radar · NCT03305016

A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency

fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD

Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

146

Actual

Start

Nov 13, 2017

Primary completion

Mar 19, 2019

Study completion Mar 19, 2019

Sponsor

Sponsor type
Industry
First posted
Oct 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A 26 week trial of TransCon hGH, a long-acting growth hormone product, administered once-a-week. Approximately 150 children (males and females) with growth hormone deficiency (GHD) will be included. All study participants will receive TransCon hGH. This is a global trial that will be conducted in, but not limited to, the United States, Canada, Australia, and New Zealand.

Conditions

  • Growth Hormone Deficiency, Pediatric
  • Endocrine System Diseases
  • Hormone Deficiency
  • Pituitary Diseases

Interventions

  • TransCon hGHDrug

    Once weekly subcutaneous injection at a starting dose of 0.24 mg/kg/week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: 26 weeks

Locations

24 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • Neufeld Medical Group Inc.

    Los Angeles, California

  • Center of Excellence in Diabetes and Endocrinology

    Sacramento, California

  • Rocky Mountain Pediatric Endocrinology

    Centennial, Colorado

  • Nemours Children's Health System

    Jacksonville, Florida

  • Orlando Health Inc.

    Orlando, Florida

  • Tallahassee Memorial Hospital

    Tallahassee, Florida

  • University of Iowa

    Iowa City, Iowa

  • Children's Minnesota

    Saint Paul, Minnesota

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire

  • NYU Winthrop Hospital

    Mineola, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • Children's Diabetes and Endocrine Center

    Portland, Oregon

  • Oregon Health & Science University

    Portland, Oregon

  • Children's Medical Center

    Dallas, Texas

  • Cook Children's Medical Center

    Fort Worth, Texas

  • University of Virginia Children's Hospital

    Charlottesville, Virginia

  • Children's Hospital of The King's Daughters

    Norfolk, Virginia

  • Monash Children's Hospital

    Clayton, Victoria, Australia

  • Stollery Children's Hospital

    Edmonton, Alberta, Canada

  • The Liggins Institute, The University of Auckland

    Grafton, Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.